Cancer Chemother Pharmacol (2014) 74:659–660
DOI 10.1007/s00280-014-2516-7

ERRATUM

Erratum to: No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers

Nianhang Chen · Daniel Weiss · Josephine Reyes · Liangang Liu · Claudia Kasserra · Xiaomin Wang · Simon Zhou · Gondi Kumar · Lilia Weiss · Maria Palmisano

Published online: 1 August 2014

Erratum to: Cancer Chemother Pharmacol (2014) 73:1031–1039
DOI 10.1007/s00280-014-2438-4

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading.

Page 1032, Subjects and methods, Study population: "body mass index of 18–33 kg/m [2], aged" should be replaced with "body mass index of 18–33 kg/m^2, aged".

Page 1033, Subjects and methods, Study design and treatment, Evaluation of lenalidomide interactions with temsirolimus: "serial blood samples were collected for 168-h after start of temsirolimus infusion" should be replaced with: "serial blood samples were collected in the first 168 h after start of temsirolimus infusion".

Page 1033, Subjects and methods, Bioanalytical methodology: "tacrolimus, and [[13] C [2, 3] H7]-temsirolimus were" should be replaced with "tacrolimus, and [^{13}C3, ^{2}H7]-temsirolimus, were".

Page 1034, Table 1: The text in the table should be aligned to the left.

The correct Table 1 is given below.

Table 1 Pharmacokinetic parameters of lenalidomide alone and in the presence of digoxin, quinidine, or temsirolimus

Pharmacokinetic parameter	Lenalidomide (10 mg)		Lenalidomide (25 mg)		Lenalidomide (25 mg)	
	Alone ($n = 17$)	+Digoxin ($n = 17$)	Alone ($n = 14$)	+Quinidine ($n = 14$)	Alone ($n = 17$)	+Temsirolimus ($n = 11$)
AUC_t (h•ng/mL)	396 (32.7)	386 (38.9)	1,288 (12.1)	1,127 (9.6)	1,276 (12.0)	1,366 (14.5)
AUC_∞ (h•ng/mL)	475 (23.2)	491 (22.2)	1,361 (12.7)	1,190 (9.8)	1,351 (11.9)	1,445 (14.5)
C_{max} (ng/mL)	119 (20.2)	118 (32.8)	367 (26.3)	337 (12.3)	364 (30.0)	361 (24.8)
T_{max} (h)	1 (1–2)	1 (1–2)	1 (0.5–3)	1 (0.5–1.5)	0.5 (0.5–2)	1 (1–2)
$t_{1/2}$ (h)	2.40 (21.0)	2.41 (17.0)	2.81 (10.1)	2.86 (12.9)	2.81 (10.5)	2.69 (9.1)
CLR (mL/min)	ND	ND	227 (18.3)	245 (11.3)	251 (16.4)	229 (15.6)
fe (% dose)	ND	ND	74.2 (11.4)	70.2 (6.6)	81.0 (10.0)	79.6 (8.0)

Geometric mean (geometric CV%) data are presented for all parameters except for T_{max} where median (range) data are presented

AUC area under the plasma concentration curve, AUC_t AUC from time zero to the last measurable concentration, AUC_∞ AUC from time zero to infinity, CL_R renal clearance, C_{max} maximum observed plasma concentration; fe, cumulative urinary excretion as a percentage of administered dose, *ND* not determined, $t_{1/2}$ z terminal-phase half-life, T_{max} time to reach C_{max}

The online version of the original article can be found under doi:10.1007/s00280-014-2438-4.

N. Chen (✉) · D. Weiss · J. Reyes · L. Liu · C. Kasserra · X. Wang · S. Zhou · G. Kumar · L. Weiss · M. Palmisano
Celgene Corporation, 86 Morris Avenue, Summit, NJ 07920, USA
e-mail: nchen@celgene.com

Page 1035, Figure 2A: “Quiridine” should be replaced with “Quinidine”.

Page 1035, Figure 2B: “Quiridine” should be replaced with “Sirolimus”.

The correct Fig. 2 is given below.



Fig. 2 Ratio of geometric means and associated 90 % confidence interval for systemic exposure (C_{max} and AUC_t) of lenalidomide (**a**) and interacting drugs (**b**) when co-administered

Page 1035, Figure 3B: “LEN + temsiroliums” should be replaced with “LEN + temsirolimus”.

The correct Fig. 3 is given below.



Fig. 3 Mean (±standard deviation) renal excretion-time profile of lenalidomide alone and in the presence of (**a**) quinidine or (**b**) temsirolimus in healthy subjects

Page 1036, Figure 4, legend: “absence and presence of lenalidoimide” should be replaced with “absence or presence of lenalidomide”.